The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Chara, Luis ^a   Sánchez Atrio, Ana ^b   Pérez, Ana ^b   Cuende, Eduardo ^b   Albarrán, Fernando ^b   Turrión, Ana ^b   Chevarria, Julio ^b   del Barco, Angel Asunsolo ^a   Sánchez, Miguel A ^a   Monserrat, Jorge ^a   Prieto, Alfredo ^a   de la Hera, Antonio ^a   Sanz, Ignacio ^c   Diaz, David ^a   Alvarez Mon, Melchor ^a,b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Clinical response; Methotrexate; Monocyte; Rheumatoid arthritis

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; METHOTREXATE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CELL COUNT; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; CELL MOTION; CLINICAL TRIAL; DEMOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

ANTIGENS, CD; ARTHRITIS, RHEUMATOID; BIOMARKERS; CASE-CONTROL STUDIES; CELL COUNT; CELL MOVEMENT; DEMOGRAPHY; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MONOCYTES; RECEPTORS, CHEMOKINE; ROC CURVE; TREATMENT OUTCOME;

EID: 84938880939     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0375-y     Document Type: Article

References (36)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094-108.
2. Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs. 2009;23:111-24.
3. Bergman MJ. Assessing adequate treatment response in patients with rheumatoid arthritis. Clin Ther. 2009;31:1219-31.
4. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-92.
5. Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther. 2006;8:R152.
6. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol. 2001;69:11-20.
7. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-64.
8. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71-82.
9. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74-80.
10. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol. 2007;19:289-95.
11. Robbins CS, Swirski FK. The multiple roles of monocyte subsets in steady state and inflammation. Cell Mol Life Sci. 2010;67:2685-93.
12. Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E, Verheijden GF, et al. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum. 2000;43:1233-43.
13. Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:S58-64.
14. Bansard C, Lequerré T, Daveau M, Boyer O, Tron F, Salier JP, et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology (Oxford). 2009;48:1021-8.
15. Chara L, Sánchez-Atrio A, Pérez A, Cuende E, Albarrán F, Turrión A, et al. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):R175.
16. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40.
17. González VM, Stewart A, Ritter PL, Lorig K. Translation and validation of arthritis outcome measures into Spanish. Arthritis Rheum. 1995;38:1429-46.
18. Böyum AJ. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest. 1968;21:77-89.
19. Swierkot J, Szechiński J. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006;58(4):473-92.
20. Feely MG, Erickson A, O'Dell JR. Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother. 2009;10(13):2095-106.
21. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res. 2010;62(8):1128-43.
22. Ponchel F, Goëb V, Parmar R, El-Sherbiny Y, Boissinot M, El Jawhari J, et al. An immunological biomarker to predict MTX response in early RA. Ann Rheum Dis. 2013;73(11):2047-53.
23. van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, et al. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum. 2009;60:12-21.
24. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol. 2003;138:501-11.
25. Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol. 2008;153:188-95.
26. Fabre S, Guisset C, Tatem L, Dossat N, Dupuy AM, Cohen JD, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol. 2009;155:395-402.
27. Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, et al. CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2002;46:2578-86.
28. Cairns AP, Crockard AD, Bell AL. The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int. 2002;21:189-92.
29. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 2012;64(3):671-7.
30. Fingerle-Rowson G, Angstwurm M, Andreesen R, Ziegler-Heitbrock HW. Selective depletion of CD14+CD16+ monocytes by glucocorticoid therapy. Clin Exp Immunol. 1998;112:501-6.
31. Dayyani F, Belge KU, Frankenberger M, Mack M, Berki T, Ziegler-Heitbrock L. Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J Leukoc Biol. 2003;74:33-9.
32. Krasselt M, Baerwald C, Wagner U, Rossol M. CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence. Arthritis Res Ther. 2013;15(5):R139.
33. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008;47:249-55.
34. Möller B, Kukoc-Zivojnov N, Okamgba S, Kessler U, Puccetti E, Ottmann OG, et al. Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors. Rheumatol Int. 2002;22:60-7.
35. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255-66.
36. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford). 2003;42:1189-96.